Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

Pharmacogenomics - 1 Jul 2012

Giovannetti Elisa, Toffalorio Francesca, De Pas Tommaso, Peters Godefridus J

Abstract excerpt

Pharmacogenetics might be used to select patients who may benefit from specific chemotherapy that best matches the individual and tumor genetic profile, thus allowing maximum activity and minimal toxicity. Even if most studies in non-small-cell lung cancer yielded contradictory results, several potential biomarkers for sensitivity/resistance to platinum compounds, gemcitabine, taxanes and pemetrexed have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Carboplatin
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Glutamates

Share to Pemetrexed

Share to Taxoids

Source

Identifiers

PMID: 22838953
DOI: 10.2217/pgs.12.91

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?PMID 22838953Read ↗

Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta-Analysis.Semantic proximity Read ↗

Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer.Semantic proximity Read ↗

Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patientsSemantic proximity Read ↗

Pharmacogenomics of platinum-based chemotherapy in NSCLCSemantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

Application of pharmacogenetics in oncologySemantic proximity Read ↗

Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsivenessSemantic proximity Read ↗

Pharmacogenomic biomarkers for personalized cancer treatment.Semantic proximity Read ↗

Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics of anticancer agents.Semantic proximity Read ↗

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.